PCM
VNDA icon

Prelude Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Prelude Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,000
Closed -$19K – 2061
2015
Q1 		$19K Buy
+2,000
New +$22.6K ﹤0.01% 1756
2014
Q1 		– Sell
-9,700
Closed -$120K – 2125
2013
Q4 		$120K Buy
+9,700
New +$97.4K 0.02% 798

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prelude Capital Management's VNDA Position: Q1 2026 in Review

Prelude Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 15,100 shares — an estimated $133K sold.

Prelude Capital Management first reported a position in VNDA in Q4 2013 and held it in 35 quarters. The position peaked at $262K in Q2 2023. 171 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Prelude Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 15,100 Vanda Pharmaceuticals shares in Q1 2026, an estimated $133K.
  • Prelude Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2013 and held it in 35 quarters.
  • Prelude Capital Management's Vanda Pharmaceuticals position peaked at $262K in Q2 2023.
  • 171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.